FDA approves Opdivo as adjuvant treatment in oesophageal or gastroesophageal junction cancer – BMS
Bristol Myers Squibb announced that the FDA has approved Opdivo (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer… read more.
